BTIG Expands Healthcare Equity Research with Life Science and Diagnostic Tools Analyst Sung Ji Nam

New York – July 10, 2017 – BTIG, LLC announced today that Sung Ji Nam has joined the firm’s Equity Research team as a Director. Based in BTIG’s New York office, she will provide coverage of the life science and diagnostic tools sector.

Ms. Nam has more than ten years of experience conducting life science and diagnostic tools equity research. Prior to joining BTIG, she was a Senior Analyst at Avondale Partners. Ms. Nam held similar roles at Cantor Fitzgerald and Gleacher & Company, where she was named an All-America Research Team Rising Star by Institutional Investor in 2011. She began her equity research career at JP Morgan, covering life science tools, diagnostics, small to mid-cap medical technology, and pharmaceutical services companies. Ms. Nam holds a BA in chemistry and an MBA, both from Harvard University.

“We are thrilled to welcome Sung Ji to our Healthcare Equity Research team,” said Karen Blando, Director of Research at BTIG. “Her understanding of the life science and diagnostic tools space will enhance our offering for institutional and corporate clients.”

BTIG’s Research and Strategy Group provides technical strategy and differentiated fundamental research across the consumer, financials, healthcare, REITs and TMT sectors. Through a diverse team of analysts, BTIG generates research on more than 250 companies under coverage. To access their latest insights, visit www.btigresearch.com.

About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 500 employees, BTIG, LLC and its affiliates operate out of 14 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs, fixed income (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global sales, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. Disclaimer: https://www.btig.com/Disclaimer

Media Contacts:
Jill Gordon
212.279.3115, ext. 226 
[email protected]

Amanda Gold
212.738.6134 
[email protected]